EGF promoter SNPs, plasma EGF levels and risk of breast cancer in Chinese women

Breast Cancer Research and Treatment

Volumn 111, Issue 2, 2008, Pages 321-327

  Wang, Yan ^a   Tian, Tian ^a   Hu, Zhibin ^a   Tang, Jinhai ^b   Wang, Shui ^a   Wang, Xuechen ^c   Qin, Jianwei ^b   Huo, Xiang ^a   Gao, Jun ^a   Ke, Qiao ^a   Jin, Guangfu ^a   Ma, Hongxia ^a   Wang, Xinru ^a   Shen, Hongbing ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b JIANGSU CANCER HOSPITAL   (China)

^c THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

Author keywords

Breast cancer; Chinese women; EGF polymorphisms; Molecular epidemiology; Plasma EGF

Indexed keywords

EPIDERMAL GROWTH FACTOR; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGE; ARTICLE; BLOOD LEVEL; BODY MASS; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CHINESE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FAMILY HISTORY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MENARCHE; MENOPAUSE; MOLECULAR EPIDEMIOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS;

ADULT; BREAST NEOPLASMS; CASE-CONTROL STUDIES; EPIDERMAL GROWTH FACTOR; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); RISK FACTORS;

EID: 48149108930     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9784-4     Document Type: Article

References (33)

1. Smiqal C, Jemal A, Wrad E, Cokkinides V, Smith R, Howe HL, Thun M (2006) Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 56:168-183
2. Yang L, Parkin DM, Ferlay J, Li L, Chen Y (2005) Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev 14:243-250
3. Yager JD, Davidson NE (2006) Estrogen Carcinogenesis in breast cancer. N Engl J Med 354:270-282
4. Sporn MB, Roberts AB (1985) Autocrine growth factors and cancer. Nature 313:745-747
5. Martinez LI, Dickson RB (1996) Dual regulation of the epidermal growth factor family of growth factors in breast cancer by sex steroids and protein Kinase C. J Steriod Biochem Mol Biol 57:1-11
6. Levin R (2003) Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol 17:309-317
7. Yarden Y (2001) The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer 37:S3-S8
8. Harari PM (2004) Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 11:689-708
9. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137
10. Garcia R, Franklin RA, McCubrev JA (2006) EGF induces cell motility and multi-drug resistance gene expression in breast cancer cells. Cell Cycle 5:2820-2826
11. Salomon DS, Brandt R, Ciardiello F, Normanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232
12. Tokunaga A, Onda M, Okuda T, Teramoto T, Fujita I, Mizutani T, Kiyama T, Yoshiyuki T, Nishi K, Matsukura N (1995) Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer. Cancer 75:1418-1425
13. Murphy LC, Dotzlaw H, Wong MS, Miller T, Mrockowski B, Gong Y, Murphy LJ (1990) Epidermal growth factor: receptor and ligand expression in human breast cancer. Semin Cancer Biol 1:305-315
14. Fenton SE,Groce NS, Lee DC (1996) Characterization of the mouse epidermal growth factor promoter and 5′-Flanking region. Role for an atypical TATA sequence. J Biol Chem 271:30870-30878
15. Mullhaupt B, Feren A, Jones A, Fodor E (2000) DNA sequence and functional characterization of the human and rat epidermal growth factor promoter: regulation by cell growth. Gene 50:191-200
16. Shahbazi M, Pravica V, Nasreen N, Fakhoury H, Fryer AA, Strange RC, Hutchinson PE, Osborne JE, Lear JT, Smith AG, Hutchinson IV (2002) Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 359:397-401
17. Jin G, Miao R, Deng Y, Hu Z, Zhou Y, Tan Y, Wang J, Hua Z, Ding W, Wang L, Chen W, Shen J, Wang X, Xu Y, Shen H (2007) Variant genotypes and haplotypes of the epidermal growth factor gene promoter are associated with a decreased risk of gastric cancer in a high-risk Chinese population. Cancer Sci 98:864-868
18. Huo X, Hu Z, Zhai X, Wang Y, Wang S, Wang X, Qin J, Chen W, Jin G, Liu J, Gao J, Wei Q, Wang X, Shen H (2007) Common non-synonymous polymorphisms in the BRCA1 associated RING Domain (BARD1) gene are associated with breast cancer susceptibility: a case-control analysis. Breast Cancer Res Treat 102:329-337
19. Stephens M, Donnelly P (2003) A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 73:1162-1169
20. Olayioye MA, Neve RM, Lane HA, Hynes NE (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19:3159-3167
21. Normanno N, Luca AD, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, Feo GD, Caponigro F, Salomon DS (2006) Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366:2-16
22. Tomaszewski J, Miturski R, Kotarski J (1996) Concentration of epidermal growth factor (EGF) in serum of women with endometrial cancer. Ginekol Pol 67:248-253
23. Pawlikowski M, Cieslak D, Stepien H, Berner J, Rybiński K (1989) Elevated blood serum levels of epidermal growth factor in some patients with gastric cancer. Endokrynol Pol 40:149-153
24. Navarro MA, Mesia R, Diez-Gibert O, Rueda A, Ojeda B, Alonso MC (1997) Epidermal growth factor in plasma and saliva of patients with active breast cancer and breast cancer patients in follow-up compared with healthy women. Breast Cancer Res Treat 42:83-86
25. Normanno N, Bianco C, Strizzi L, Mancino M, Maiello MR, De Luca A, Caponigro F, Salomon DS (2005) The ErbB receptors and their ligands in cancer: an overview. Curr Drug Targets 6:243-257
26. McCarron SL, Bateman AC, Theaker JM, Howell WM (2003) EGF +61 gene polymorphism and susceptibility to and prognostic markers in cutaneous malignant melanoma. Int J Cancer 107:673-675
27. Bhowmick DA, Zhuang Z, Wait SD, Weil RJ (2004) A functional polymorphism in the EGF gene is found with increased frequency in glioblastoma multiforme patients and is associated with more aggressive disease. Cancer Res 64:1220-1223
28. Amend KL, Elder JT, Tomsho LP, Bonner JD, Johnson TM, Schwartz J, Berwick M, Gruber SB (2004) EGF gene polymorphism and the risk of incident primary melanoma. Cancer Res 64:2668-2672
29. Randerson-Moor JA, Gaut R, Turner F, Whitaker L, Barrett JH, Silva Idos S, Swerdlow A, Bishop DT, Bishop JA (2004) The relationship between the epidermal growth factor (EGF) 5′UTR variant A61G and melanoma/nevus susceptibility. J Invest Dermatol 123:755-759
30. James MR, Hayward NK, Dumenil T, Montgomery GW, Martin NG, Duffy DL (2004) Epidermal growth factor gene (EGF) polymorphism and risk of melanocytic neoplasia. J Invest Dermatol 123:760-762
31. Hamai Y, Matsumura S, Matsusaki K, Kitadai Y, Yoshida K, Yamaguchi Y, Imai K, Nakachi K, Toge T, Yasui W (2005) A single nucleotide polymorphism in the 5-untranslated region of the EGF gene is associated with occurrence and malignant progression of gastric cancer. Pathobiology 72:133-138
32. Goto Y, Ando T, Goto H, Hamajima N (2005) No association between EGF gene polymorphism and gastric cancer. Cancer Epidemiol Biomarkers Prev 14:2454-2456
33. Costa BM, Ferreira P, Costa S, Canedo P, Oliveira P, Silva A, Pardal F, Suriano G, Machado JC, Lopes JM, Reis RM (2007) Association between functional EGF+61 polymorphism and glioma risk. Clin Cancer Res 13:2621-2626